A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Phase 3
900
about 5.6 years
50–85
29 sites in CA, CO, CT +14
About this study
This trial is testing a treatment called prasinezumab compared to a placebo in people with early-stage Parkinson's disease. The goal is to see if prasinezumab helps manage symptoms, is safe, and how it works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Prasinezumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
Primary: Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score
Secondary: Change From Baseline in Motor Function as Measured by the MDS-UPDRS Part III off Medication Score, Percentage of Participants With Adverse Events of Special Interest (AESI), Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Neurology